---
category: news
title: "Xen­cor says good­bye to its for­mer lead drug, sell­ing all rights to Lon­nie Moul­der's new start­up"
excerpt: "More than three years after its lead program failed a Phase II study, Xencor is passing off the drug to an up-and-coming Hong Kong biotech. Xencor sold exclusive worldwide rights for obexelimab, a bispecific targeting FcγRIIb and CD19 to treat autoimmune diseases,"
publishedDateTime: 2021-11-22T12:15:00Z
originalUrl: "https://endpts.com/xencor-says-goodbye-to-its-former-lead-drug-selling-all-rights-to-lonnie-moulders-new-startup/"
webUrl: "https://endpts.com/xencor-says-goodbye-to-its-former-lead-drug-selling-all-rights-to-lonnie-moulders-new-startup/"
type: article
quality: 0
heat: 0
published: false

provider:
  name: ENDPOINTS NEWS
  domain: endpts.com

topics:
  - AI

secured: "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;SymsqG1dG4yaeeWaDaXe9g=="
---

